Home » Preliminary Data Suggest Spasticity May Be Reduced in RRMS Patients Who Transitioned to COPAXONE
Preliminary Data Suggest Spasticity May Be Reduced in RRMS Patients Who Transitioned to COPAXONE
Teva Pharmaceutical announced interim data from a prospective, open label survey study evaluating spasticity in patients with relapsing-remitting multiple sclerosis (RRMS) who transitioned to Copaxone (glatiramer acetate injection) from interferon-beta treatment.
Benzinga
Benzinga
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May